Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555996 | 1.00 | GSK3B (0.52) | GSK3BMAOBL3MBTL1PTK2EGLN1 | |
| Bromide SCHEMBL7486985 | 0.98 | MAOB (0.50) | GSK3BMAOBL3MBTL1PTK2EGLN1 | |
| Bromide SCHEMBL31116818 | 0.98 | MAOB (0.50) | GSK3BMAOBL3MBTL1PTK2EGLN1 | |
| SCHEMBL9823916 | 0.82 | MAOB (0.57) | GSK3BMAOBL3MBTL1PTK2EGLN1 | |
| SCHEMBL30983702 | 0.82 | MAOB (0.57) | GSK3BMAOBL3MBTL1PTK2EGLN1 | |
| SCHEMBL12780420 | 0.81 | MAOB (0.51) | MAOBL3MBTL1PTK2EGLN1TDP1 | |
| SCHEMBL16601084 | 0.78 | PTPN1 (0.50) | GSK3BALDH1A1 | |
| SCHEMBL1438181 | 0.78 | ALDH1A1 (0.62) | GSK3BMEN1ALDH1A1KMT2A | |
| SCHEMBL30998305 | 0.78 | ALDH1A1 (0.62) | GSK3BMEN1ALDH1A1KMT2A | |
| SCHEMBL10815017 | 0.77 | MAOB (0.55) | MAOBL3MBTL1PTK2EGLN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | ATROGI AB (SE) | 2024-07-16 | — | — | US | disclosed |
| EP-4393914-A1 | IMIDAZOCYCLIC COMPOUND AND APPLICATION THEREOF | Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118176185-A | 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application | 上海翰森生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| EP-4209490-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2023-07-12 | — | — | EP | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078392-A1 | 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-115884969-A | Condensed imidazole derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| WO-2010011964-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-1045833-B1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6608070-B1 | Useful for treatment of medical condition in which prostaglandins are implicated as pathogens | NAKAO KAZUNARI (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1065206-B1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER (US) | 2002-10-09 | — | — | EP | disclosed |
| CN-1284064-A | 2,3-substituted indole compounds as cox-2 inhibitors | PFIZER PHARMA (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1065206-A1 | Tetrazolylalkyl indole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1045833-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER INC. (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999035130-A1 | 2,3-SUBSTITUTED INDOLE COMPOUNDS AS COX-2 INHIBITORS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | GSK3B 466/4885MAOB 246/4885L3MBTL1 589/4885 |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | GSK3B 983/4885MAOB 2431/4885L3MBTL1 4437/4885 |
| US-12036210-B2 | Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia | SLC5A2, SLC5A1, GPR119 | GSK3B 949/4885MAOB 739/4885L3MBTL1 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.